Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (571-580 of 706) with videos related to

Pageof 71
Sort By:
JAMA Cardiology|May 1, 2018
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical TrialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Diabetes, Obesity & Metabolism|January 7, 2017
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trialSimon R Heller, Richard M Bergenstal, William B White, et al.
European Heart Journal|June 3, 2017
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trialEmmanuelle Vidal-Petiot, Amanda Stebbins, Karen Chiswell, et al.
American Heart Journal|June 1, 2002
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert ProgramChristopher P Cannon, Mary H Hand, Raymond Bahr, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Clinical Cardiology|May 27, 2021
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)David S Eccleston, Joseph M Kim, Jurien M Ten Berg, et al.
JAMA Cardiology|June 20, 2019
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled TrialsRenato D Lopes, Hwanhee Hong, Ralf E Harskamp, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Journal of the American College of Cardiology|November 16, 2017
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI RegistryAvinainder Singh, Bradley L Collins, Ankur Gupta, et al.
JACC. Cardiovascular Interventions|December 7, 2019
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrien M Ten Berg, Anne de Veer, Jonas Oldgren, et al.
Pageof 71

Showing results (571-580 of 706) with videos related to

Sort By:
Pageof 71
JAMA Cardiology|May 1, 2018
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical TrialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Diabetes, Obesity & Metabolism|January 7, 2017
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trialSimon R Heller, Richard M Bergenstal, William B White, et al.
European Heart Journal|June 3, 2017
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trialEmmanuelle Vidal-Petiot, Amanda Stebbins, Karen Chiswell, et al.
American Heart Journal|June 1, 2002
Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert ProgramChristopher P Cannon, Mary H Hand, Raymond Bahr, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Clinical Cardiology|May 27, 2021
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)David S Eccleston, Joseph M Kim, Jurien M Ten Berg, et al.
JAMA Cardiology|June 20, 2019
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled TrialsRenato D Lopes, Hwanhee Hong, Ralf E Harskamp, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Journal of the American College of Cardiology|November 16, 2017
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI RegistryAvinainder Singh, Bradley L Collins, Ankur Gupta, et al.
JACC. Cardiovascular Interventions|December 7, 2019
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrien M Ten Berg, Anne de Veer, Jonas Oldgren, et al.
Pageof 71